Results 221 to 230 of about 195,645 (350)

Idiopathic pulmonary fibrosis - Part 1: Diagnosis [PDF]

, 2001
R Erbes, M. Raffenberg, H. Lode
openalex   +1 more source

Clinical Outcomes After Catheter Ablation in Cardiac Sarcoidosis and Idiopathic Nonischemic Cardiomyopathy

Journal of Cardiovascular Electrophysiology, EarlyView.
Catheter ablation for recurrent ventricular tachycardia. ABSTRACT Introduction Cardiac sarcoidosis (CS) may present clinically with ventricular tachycardia (VT). Since the diagnosis is challenging, clinical manifestations and imaging findings are commonly used to identify probable CS in patients without histological diagnosis or extracardiac ...
Kenji Hashimoto, Samual Turnbull, Max Bickley, Ashwin Bhaskaran, Kaimin Huang, Kasun De Silva, Saurabh Kumar   +6 more
wiley   +1 more source

Idiopathic pulmonary fibrosis with bronchogenic carcinoma

Lung India, 2009
Idiopathic pulmonary fibrosis is essentially a benign disease. We present a case of 65-year-old female patient who presented with left-sided chest pain and breathlessness.
Nair Girija, Swami Shivani, Mehta Ankur
doaj  

Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia [PDF]

, 2002
Y YANG, Jiro Fujita, Shuji Bandoh, Y Ohtsuki, Ichiro Yamadori, Takeo Yoshinouchi, Toshihiko Ishida   +6 more
openalex   +1 more source

Long‐Term Follow‐Up of Inducible Bundle Branch Reentrant Ventricular Tachycardia in Patients Without Structural Heart Disease: Beyond the Electrophysiology Laboratory

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Bundle branch reentrant ventricular tachycardia (BBR‐VT) is a rare form of VT occurring in patients with structural heart disease (SHD). Rarely, it can also occur in the absence of SHD. Understanding its clinical and electrophysiologic (EP) properties and outcomes post‐catheter ablation (CA) is crucial. Objective We present a series
Muhieddine Omar Chokr, Haroldo Heitor Ribeiro Filho, Roberto Alvarez Coello, Rodrigo Melo Kulchetscki, Lucas Moura, Francisco Darrieux, Denise T. Hachul, Luciana Sacilotto, Tan C. Wu, Pedro M. Vandoni, Italo B. Souza, Pedro Linhares, Cristiano F. Pisani, Carina A. Hardy, Mauricio I. Scanavacca   +14 more
wiley   +1 more source

Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis

, 2000
K Tsukamoto
openalex   +1 more source

Serum surfactant proteins‐A and ‐D as biomarkers in idiopathic pulmonary fibrosis [PDF]

, 2002
Kelly E. Greene, Talmadge E. King, Y. Kuroki, Becki Bucher‐Bartelson, Gary W. Hunninghake, Lee S. Newman, Hisato Nagae, Robert J. Mason   +7 more
openalex   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

Assessing health status and quality of life in idiopathic pulmonary fibrosis: which measure should be used?

, 2000
Jolanda De Vries, A SEEBREGTS, Marjolein Drent   +2 more
openalex   +1 more source

Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis [PDF]

, 2002
Hiroaki Satoh
openalex   +1 more source